Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ImmunoGen, Inc.    IMGN

IMMUNOGEN, INC. (IMGN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

FDA Approves Kadcyla, Breast-Cancer Drug from Roche, ImmunoGen

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/22/2013 | 05:26pm CET
   By Jennifer Corbett Dooren 
 

WASHINGTON--The U.S. Food and Drug Administration Friday approved a powerful new type of drug that will be marketed by Roche Holding AG (ROG.VX, RHHBY) to treat breast cancer.

The drug called, Kadcyla, combines Roche's existing cancer drug, Herceptin, with a powerful chemotherapy agent.

Herceptin targets a protein called HER2 found on tumors in about 20% to 25% of breast-cancer patients. The two other components of Kadcyla, both developed by ImmunoGen Inc. (>> ImmunoGen, Inc.), are a chemotherapy agent called emtansine that is too potent to be delivered as a conventional medicine, and a linker that connects the two drugs. Herceptin then delivers the package to the tumor cell, where it releases the toxic cargo to kill the cancer.

The FDA's approval of Kadcyla, which was previously known as T-DM1, triggers a $10.5 million payment to ImmunoGen by Roche. ImmunoGen will also receive royalties on sales.

Roche's Genentech unit said Kadcyla will be available to patients in about two weeks. The drug will be priced at $9,800 a month. The company said there will be a patient-assistance program to help pay for the product.

The approval of Kadcyla was based on a study of about 1,000 women with HER2-positive breast cancer who had been treated previously with Herceptin and a traditional chemotherapy drug. About half of the women were then treated with T-DM1 and the other half were treated with a combination of Xeloda, another Roche drug, and GlaxoSmithKline PLC's (GSK, GSK.LN) Tykerb. The drugs were administered every three weeks until the disease progressed or patients experienced unmanageable side effects.

The study was designed to measure progression-free survival, which is a measurement of the time from the start of treatment until the disease gets worse or the patient dies, and overall survival, which is a measurement of time from the start of treatment until death.

The median progression-free survival for patients receiving T-DM1 was 9.6 months, compared with 6.4 months in the group receiving Xeloda and Tykerb, a difference considered statistically significant. The median overall survival was 30.9 months in the Kadcyla group and 25.1 months for Xeloda and Tykerb group.

Write to Jennifer Corbett Dooren at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : ImmunoGen, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMMUNOGEN, INC.
12/09 IMMUNOGEN : Presents New Clinical and Preclinical Data at ASH Annual Meeting
11/17 IMMUNOGEN : Biotechnology and Oncology Markets Have Positive Projections
11/09 IMMUNOGEN : to Present New Data on Novel Antibody-Drug Conjugates at 59th ASH An..
11/09 IMMUNOGEN : Management's Discussion and Analysis of Financial Condition and Resu..
11/07 IMMUNOGEN : Announces Webcasts of Presentations at Upcoming Conferences
11/03 IMMUNOGEN, INC. (NASDAQ : IMGN) reported earnings of ($0.61) per share missing W..
11/03 IMMUNOGEN : reports 3Q loss
11/03 IMMUNOGEN INC : Results of Operations and Financial Condition, Financial Stateme..
11/03 IMMUNOGEN : Reports Recent Progress and Third Quarter 2017 Operating Results
11/02 IMMUNOGEN : Patent Issued for Methods for the Acylation of Maytansinol (USPTO 97..
More news
News from SeekingAlpha
12/11 NASDAQ BIOTECH INDEX : 54 to be added, 15 removed
12/01 ImmunoGen (IMGN) Presents At Evercore ISI Biopharma Catalyst/Deep Dive Confer..
11/16 ImmunoGen (IMGN) Presents At Jefferies 2017 London Healthcare Conference - Sl..
11/15 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
11/03 Immunogen's (IMGN) CEO Mark Enyedy on Q3 2017 Results - Earnings Call Transcr..
Financials ($)
Sales 2016 69,2 M
EBIT 2016 -113 M
Net income 2016 -131 M
Debt 2016 19,2 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 14,7x
Capi. / Sales 2017 8,52x
Capitalization 995 M
Chart IMMUNOGEN, INC.
Duration : Period :
ImmunoGen, Inc. Technical Analysis Chart | IMGN | US45253H1014 | 4-Traders
Technical analysis trends IMMUNOGEN, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 9,50 $
Spread / Average Target 48%
EPS Revisions
Managers
NameTitle
Mark J. Enyedy President, Chief Executive Officer & Director
Stephen C. McCluski Chairman
David B. Johnston Chief Financial Officer & Executive Vice President
Richard J. Gregory Chief Scientific Officer & Executive VP
Anna Berkenblit Chief Medical Officer & Vice President
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOGEN, INC.232.84%995
CELLTRION, INC.--.--%23 643
IQVIA HOLDINGS INC34.41%21 105
INCYTE CORPORATION-2.16%20 253
LONZA GROUP62.09%19 941
ALNYLAM PHARMACEUTICALS, INC.233.49%12 160